Early intensification treatment approach in advanced-stage hodgkin lymphoma

Hematology/Oncology Clinics of North America

Volumn 28, Issue 1, 2014, Pages 65-74

  Borchmann, Peter ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

BEACOPP; Evidence; Hodgkin lymphoma; Overall survival

Indexed keywords

ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADVANCED CANCER; ANTIBIOTIC THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; DRUG MEGADOSE; FOLLOW UP; HEALTH CARE QUALITY; HODGKIN DISEASE; HUMAN; HYPOGONADISM; LEUKOPENIA; MENTAL STRESS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; RECURRENCE FREE SURVIVAL; REMISSION; REVIEW; RISK FACTOR; SEXUAL FUNCTION; THROMBOCYTOPENIA;

BEACOPP; EVIDENCE; HODGKIN LYMPHOMA; OVERALL SURVIVAL;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 84888795256     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.10.002     Document Type: Review

References (30)

1. Connors J.M. Hodgkin's lymphoma-the great teacher. NEngl J Med 2011, 365(3):264-265.
2. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. NEngl J Med 2003, 348(24):2386-2395.
3. Borchmann P., Kreissl S., Diehl V., et al. Treatment of advanced-stage Hodgkin lymphoma: let us face the facts. JClin Oncol 2013, 31(24):3045-3046.
4. Longo D.L. Reply to P. Borchmann etal. JClin Oncol 2013, 31(24):3046.
5. Longo D.L. Treatment of advanced hodgkin lymphoma: the more things change, the more they stay the same. JClin Oncol 2013, 31(6):660-662.
6. Engert A., Diehl V., Franklin J., et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. JClin Oncol 2009, 27:4548-4554.
7. Borchmann P., Haverkamp H., Diehl V., et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. JClin Oncol 2011, 29(32):4234-4242.
8. Engert A., Haverkamp H., Kobe C., et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012, 379(9828):1791-1799.
9. Kobe C., Dietlein M., Franklin J., et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008, 112(10):3989-3994.
10. Andre M., Bosly A. BEACOPP escalated versus ABVD in advanced Hodgkin's lymphoma. Lancet Oncol 2013, 14(10):911-912.
11. Wongso D., Fuchs M., Plutschow A., et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin study Group. JClin Oncol 2013, 31(22):2819-2824.
12. Behringer K., Mueller H., Goergen H., et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. JClin Oncol 2013, 31(2):231-239.
13. Behringer K., Muller H., Gorgen H., et al. Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group. Br J Cancer 2013, 108(1):49-57.
14. Turner S., Maher E.J., Young T., et al. What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. Br J Cancer 1996, 73(2):222-227.
15. Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. JClin Oncol 2003, 21(18):3431-3439.
16. Engert A., Ballova V., Haverkamp H., et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. JClin Oncol 2005, 23(22):5052-5060.
17. Levis A., Depaoli L., Urgesi A., et al. Probability of cure in elderly Hodgkin's disease patients. Haematologica 1994, 79(1):46-54.
18. Ballova V., Ruffer J.U., Haverkamp H., et al. Aprospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol 2005, 16(1):124-131.
19. Enblad G., Glimelius B., Sundstrom C. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol 1991, 2(4):297-302.
20. Bohlius J., Reiser M., Schwarzer G., et al. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 2003, 122(3):413-423.
21. Doorduijn J.K., van der Holt B., van Imhoff G.W., et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. JClin Oncol 2003, 21(16):3041-3050.
22. Halbsguth T.V., Nogova L., Mueller H., et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2010, 116(12):2026-2032.
23. Proctor S.J., Wilkinson J., Jones G., et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012, 119(25):6005-6015.
24. Evens A.M., Hong F., Gordon L.I., et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 2013, 161(1):76-86.
25. Slevin M.L., Stubbs L., Plant H.J., et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990, 300(6737):1458-1460.
26. Skoetz N., Trelle S., Rancea M., et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013, 14(10):943-952.
27. Viviani S., Zinzani P.L., Rambaldi A., et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. NEngl J Med 2011, 365(3):203-212.
28. Federico M., Luminari S., Iannitto E., et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. JClin Oncol 2009, 27(5):805-811.
29. Carde P, Mounier N. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Annual Meeting of the Amercian Society of Clinical Oncology. Chicago, June 14-17, 2012. p. 8002.
30. Mounier N., Brice P., Bologna S., et al. ABVD (eight cycles) versus BEACOPP (4escalated cycles to 4 baseline) in stages III-IV low risk Hodgkin lymphoma (IPS 0-2): final results of the LYSA H34 trial. Hematol Oncol 2013, 31(Suppl 1):96-150. [abs 127].